{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:08:38Z","timestamp":1779797318705,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40259-026-00779-9","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:34:31Z","timestamp":1777314871000},"page":"497-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan\u2019s C-CAT Registry"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8694","authenticated-orcid":false,"given":"Yasuyoshi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunaga","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raito","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoh","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"779_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"779_CR2","doi-asserted-by":"publisher","first-page":"19427","DOI":"10.18632\/oncotarget.24827","volume":"9","author":"M Cis\u0142o","year":"2018","unstructured":"Cis\u0142o M, Filip AA, Arnold Offerhaus GJ, Cise\u0142 B, Rawicz-Pruszy\u0144ski K, Skierucha M, et al. Distinct molecular subtypes of gastric cancer: from Laur\u00e9n to molecular pathology. Oncotarget. 2018;9:19427\u201342. https:\/\/doi.org\/10.18632\/oncotarget.24827.","journal-title":"Oncotarget"},{"key":"779_CR3","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"779_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"779_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, Bai Y, Ryu M-H, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"key":"779_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.21037\/jgo-22-1133","volume":"14","author":"RD Peixoto","year":"2023","unstructured":"Peixoto RD, Mathias-Machado MC, J\u00e1come A, Gil M, Fogacci J, Sodr\u00e9 B, et al. PD-L1 testing in advanced gastric cancer\u2014what physicians who treat this disease must know\u2014a literature review. J Gastrointest Oncol. 2023;14:1560\u201375. https:\/\/doi.org\/10.21037\/jgo-22-1133.","journal-title":"J Gastrointest Oncol"},{"key":"779_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s10120-024-01571-w","volume":"28","author":"H Abe","year":"2025","unstructured":"Abe H, Kuwata T, Kushima R, Ushiku T. Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric Cancer. 2025;28:294\u2013300. https:\/\/doi.org\/10.1007\/s10120-024-01571-w.","journal-title":"Gastric Cancer"},{"key":"779_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895\u2013902. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0275.","journal-title":"JAMA Oncol"},{"key":"779_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27:907\u201331. https:\/\/doi.org\/10.1007\/s10120-024-01523-4.","journal-title":"Gastric Cancer"},{"key":"779_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"779_CR11","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. 2021;32:1626\u201336. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.016.","journal-title":"Ann Oncol"},{"key":"779_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","volume":"8","author":"DM Merino","year":"2020","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen S-J, White JR, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8:e000147. https:\/\/doi.org\/10.1136\/jitc-2019-000147.","journal-title":"J Immunother Cancer"},{"key":"779_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81667-w","volume":"11","author":"H Nakano","year":"2021","unstructured":"Nakano H, Saito M, Nakajima S, Saito K, Nakayama Y, Kase K, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep. 2021;11:1982. https:\/\/doi.org\/10.1038\/s41598-021-81667-w.","journal-title":"Sci Rep"},{"key":"779_CR14","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3390\/cancers16112062","volume":"16","author":"G Angelico","year":"2024","unstructured":"Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E, et al. ARID1A mutations in gastric cancer: a review with focus on clinicopathological features, molecular background and diagnostic interpretation. Cancers (Basel). 2024;16:2062. https:\/\/doi.org\/10.3390\/cancers16112062.","journal-title":"Cancers (Basel)."},{"key":"779_CR15","doi-asserted-by":"publisher","first-page":"15767","DOI":"10.1038\/s41598-019-52414-z","volume":"9","author":"J Yao","year":"2019","unstructured":"Yao J, Gong Y, Zhao W, Han Z, Guo S, Liu H, et al. Comprehensive analysis of POLE and POLD1 gene variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci Rep. 2019;9:15767. https:\/\/doi.org\/10.1038\/s41598-019-52414-z.","journal-title":"Sci Rep"},{"key":"779_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41698-025-01052-y","volume":"9","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Li J. Immunotherapy for diffuse gastric cancer: challenges and new avenues. NPJ Precis Oncol. 2025;9:247. https:\/\/doi.org\/10.1038\/s41698-025-01052-y.","journal-title":"NPJ Precis Oncol."},{"key":"779_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/cas.14754","volume":"112","author":"Y Mukai","year":"2021","unstructured":"Mukai Y, Ueno H. Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci. 2021;112:970\u20137. https:\/\/doi.org\/10.1111\/cas.14754.","journal-title":"Cancer Sci"},{"key":"779_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, Sudo T, Tamai I, Shiraishi Y, et al. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discov. 2022;12:2509\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0417.","journal-title":"Cancer Discov"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"779_CR20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood.2023022222","volume":"142","author":"LD Weeks","year":"2023","unstructured":"Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023;142:2235\u201346. https:\/\/doi.org\/10.1182\/blood.2023022222.","journal-title":"Blood"},{"key":"779_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180065","author":"WG Dunn","year":"2024","unstructured":"Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Investig. 2024. https:\/\/doi.org\/10.1172\/JCI180065.","journal-title":"J Clin Investig"},{"key":"779_CR22","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-18-1201","volume":"24","author":"CC Coombs","year":"2018","unstructured":"Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, et al. identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res. 2018;24:5918\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1201.","journal-title":"Clin Cancer Res"},{"key":"779_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000549852","author":"S Oya","year":"2025","unstructured":"Oya S, Sato Y, Asaoka R, Sugawara K, Okamoto A, Miwa Y, et al. Lymphatic metastasis predicts better response to nivolumab in recurrent or metastatic gastric cancer: insights from tumor-draining lymph node immunity and long-term outcomes. Oncology. 2025. https:\/\/doi.org\/10.1159\/000549852.","journal-title":"Oncology"},{"key":"779_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, et al. Nonoperative management of mismatch repair\u2013deficient tumors. N Engl J Med. 2025;392:2297\u2013308. https:\/\/doi.org\/10.1056\/NEJMoa2404512.","journal-title":"N Engl J Med"},{"key":"779_CR25","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1038\/s41598-021-99364-z","volume":"11","author":"K Shimozaki","year":"2021","unstructured":"Shimozaki K, Hayashi H, Tanishima S, Horie S, Chida A, Tsugaru K, et al. Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. Sci Rep. 2021;11:20003. https:\/\/doi.org\/10.1038\/s41598-021-99364-z.","journal-title":"Sci Rep"},{"key":"779_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMc2306877","volume":"388","author":"Y Usui","year":"2023","unstructured":"Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med. 2023;388:1181\u201390. https:\/\/doi.org\/10.1056\/NEJMc2306877.","journal-title":"N Engl J Med"},{"key":"779_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.gie.2016.03.791","volume":"84","author":"S Shichijo","year":"2016","unstructured":"Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84:618\u201324. https:\/\/doi.org\/10.1016\/j.gie.2016.03.791.","journal-title":"Gastrointest Endosc"},{"key":"779_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-309252.","journal-title":"Gut"},{"key":"779_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMra1314704","volume":"371","author":"SJ Spechler","year":"2014","unstructured":"Spechler SJ, Souza RF. Barrett\u2019s esophagus. N Engl J Med. 2014;371:836\u201345. https:\/\/doi.org\/10.1056\/NEJMra1314704.","journal-title":"N Engl J Med"},{"key":"779_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.exphem.2022.09.003","volume":"115","author":"X Gao","year":"2022","unstructured":"Gao X, You X, Droin N, Banaszak LG, Churpek J, Padron E, et al. Role of ASXL1 in hematopoiesis and myeloid diseases. Exp Hematol. 2022;115:14\u20139. https:\/\/doi.org\/10.1016\/j.exphem.2022.09.003.","journal-title":"Exp Hematol"},{"key":"779_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01698-8","volume":"16","author":"JE Tovar Perez","year":"2024","unstructured":"Tovar Perez JE, Zhang S, Hodgeman W, Kapoor S, Rajendran P, Kobayashi KS, et al. Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception. Clin Epigenet. 2024;16:83. https:\/\/doi.org\/10.1186\/s13148-024-01698-8.","journal-title":"Clin Epigenet"},{"key":"779_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/intimm\/dxaf020","volume":"37","author":"Y Momoi","year":"2025","unstructured":"Momoi Y, Kumagai S, Nishikawa H. Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution. Int Immunol. 2025;37:521\u201341. https:\/\/doi.org\/10.1093\/intimm\/dxaf020.","journal-title":"Int Immunol"},{"key":"779_CR33","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1013343.","journal-title":"N Engl J Med"},{"key":"779_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01336-x","volume":"15","author":"EA Medina","year":"2022","unstructured":"Medina EA, Delma CR, Yang F-C. ASXL1\/2 mutations and myeloid malignancies. J Hematol Oncol. 2022;15:127. https:\/\/doi.org\/10.1186\/s13045-022-01336-x.","journal-title":"J Hematol Oncol"},{"key":"779_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.6871","volume":"13","author":"L Yang","year":"2024","unstructured":"Yang L, Wei X, Gong Y. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Cancer Med. 2024;13:1\u201313. https:\/\/doi.org\/10.1002\/cam4.6871.","journal-title":"Cancer Med"},{"key":"779_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100036","volume":"6","author":"F Pietrantonio","year":"2021","unstructured":"Pietrantonio F, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6:100036. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100036.","journal-title":"ESMO Open"},{"key":"779_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.19.02105","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33:929\u201338. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"Ann Oncol"},{"key":"779_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7:183. https:\/\/doi.org\/10.1186\/s40425-019-0647-4.","journal-title":"J Immunother Cancer"},{"key":"779_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner R, Longshore JW, L\u00f3pez-R\u00edos F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4:e000442. https:\/\/doi.org\/10.1136\/esmoopen-2018-000442.","journal-title":"ESMO Open"},{"key":"779_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00694-8","volume":"8","author":"J Wang","year":"2024","unstructured":"Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W, et al. Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer. npj Precis Oncol. 2024;8:214. https:\/\/doi.org\/10.1038\/s41698-024-00694-8.","journal-title":"npj Precis Oncol"},{"key":"779_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004703","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhang Q, Qi C, Bai Y, Zhao F, Chen H, et al. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR\/MSI-H gastrointestinal cancer. J Immunother Cancer. 2022;10:e004703. https:\/\/doi.org\/10.1136\/jitc-2022-004703.","journal-title":"J Immunother Cancer"},{"key":"779_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113356","volume":"23","author":"ECY Lee","year":"2022","unstructured":"Lee ECY, Kok JST, Teh BT, Lim KS. Interplay between the DNA damage response and immunotherapy response in cancer. Int J Mol Sci. 2022;23:13356. https:\/\/doi.org\/10.3390\/ijms232113356.","journal-title":"Int J Mol Sci"},{"key":"779_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10388-021-00835-z","volume":"18","author":"E Booka","year":"2021","unstructured":"Booka E, Tsubosa Y, Yokota T, Mayanagi S, Ishii K, Urakami K, et al. Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA. Esophagus. 2021;18:743\u201352. https:\/\/doi.org\/10.1007\/s10388-021-00835-z.","journal-title":"Esophagus"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00779-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00779-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00779-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:46:02Z","timestamp":1779795962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00779-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00779-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"5 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuyoshi Sato reports personal fees (honoraria for lectures) from Ono Pharmaceutical Co., Ltd. and Bristol Myers Squibb outside the submitted work. These companies had no role in the study design, data collection, data analysis, decision to publish, or preparation of the manuscript. Koichi Yagi, Kazunaga Ishigaki, Raito Asaoka, Kotaro Sugawara, Shuichiro Oya, Asami Okamoto, Yoshiyuki Miwa, Shoh Yajima, Yoshifumi Baba, Kousuke Watanabe, Katsutoshi Oda, and Mitsuhiro Fujishiro declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the Ethics Committee of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (no. 2021341G), and the C-CAT Data Utilization Review Board (no. CDU2022-026N). This retrospective study used deidentified registry data obtained under the above approvals. The requirement for individual informed consent was waived by both committees owing to the retrospective design and use of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individually identifiable images or data are presented. Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets analyzed during the current study were obtained from the C-CAT database under data-use agreements and are not publicly available. Deidentified data may be accessible upon reasonable request to C-CAT and with the required institutional approvals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Yasuyoshi Sato conceived and designed the study, curated the dataset, performed the statistical analyses, interpreted the results, prepared figures and tables, and drafted the manuscript. Koichi Yagi, Kazunaga Ishigaki, Raito Asaoka, Kotaro Sugawara, Shuichiro Oya, Asami Okamoto, Yoshiyuki Miwa, Shoh Yajima, Yoshifumi Baba, and Mitsuhiro Fujishiro contributed to writing, review, and editing. Kousuke Watanabe and Katsutoshi Oda contributed to project administration for this studyand to writing, review, and editing. All authors, including Yasuyoshi Sato, critically revised the manuscript, approved the final version, and agreed to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}